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Abstract. The current standard for prenatal screening is 
mostly based on biochemical marker tests and the use of 
ultrasonography. There is no secure stand-alone screening 
marker for congenital heart defects (CHDs). MicroRNAs 
(miRNAs) that are associated with cardiogenesis enter the 
maternal peripheral bloodstream during pregnancy and allow 
non-invasive prenatal testing (NIPT). The present study inves-
tigated the plasma expression profile of fetal hsa-miR-99a in 
maternal blood. Peripheral blood samples were collected from 
39 pregnant patients, comprising 22 with CHD-positive fetuses 
and 17 with CHD-free controls. miRNAs were isolated from 
the maternal serum and reverse transcription-quantitative 
polymerase chain reaction was carried out to determine the 
expression of hsa-miR-99a. While the miRNA concentra-
tions were almost identical among the affected and control 
groups (5.54 vs. 6.40 ng/µl), significantly upregulated 
hsa-miR-99a levels were identified in the affected group 
(1.78x10-2±3.53x10-2 vs. 1.09x10-3±3.55x10-3 ng/µl, P=0.038). 
In conclusion, according to the present study, hsa-miR-99a 
is involved in cardiac malformation and may serve as a 
biomarker during fetal development, and therefore presents as 
a candidate for monitoring cardiomyogenesis and potential use 
as a NIPT-biomarker for fetal CHD.
Introduction
Congenital heart defects (CHDs) represent the most common 
form of major birth defects currently affecting ~1% of live 
births (1). The introduction of reliable markers for early 
screening and identification of CHDs is likely to reduce the 
morbidity and mortality of the affected neonates, the economic 
burden placed on the National Health Service (NHS) and 
the stress placed on families, including proactive medical 
treatment and parental counseling regarding options during 
the pregnancy following detection.
The present detection methods of screening CHDs 
comprise fetal echocardiography and various biomarkers, 
such as β-human-chorionic-gonadotropin (β-hCG) and preg-
nancy-associated plasma protein A (PAPP-A); however, none 
of them establish specific indices without high incidences of 
false‑positive results. Recent studies have identified specific 
microRNAs (miRNAs) associated with cardiogenesis, linked 
positively to placental miRNA expression. Detection of these 
in maternal peripheral blood during pregnancy allows for novel 
biomarkers used for screening and validating fetal CHDs.
While the reported birth prevalence differs worldwide, 
the estimate of 8/1,000 live births is generally accepted as 
the best approximation (1). Rosano et al (2) linked ~20% of 
infant fatalities to anomalies present at birth; CHDs account 
for 28% of mortalities during the neonatal period and 50% in 
the first 2‑12 months of life (2,3).
Studies have reported 25-50% of cases with CHD as severe, 
requiring invasive diagnostics, and one or more surgical 
procedures within the neonatal period or during infancy (4,5). 
Frequently, the affected children struggle with more than heart 
disease due to the associated defects in other organ systems 
and substantial neurodevelopmental problems (6). In a state-
ment of the American Heart Association, Marino et al (7) 
reported moderate to severe neurodevelopmental disabilities 
in >50% of neonates born with severe cardiac defects and in 
25% of those with less severe malformations.
Prenatal ultrasonography (US) constitutes one of several 
standard-screening tools in current obstetric care. Routinely 
performed at gestational weeks 18-20, fetal echocardiography 
indicates CHDs by examination of a four-chamber view and 
additional visualization of the outflow tracts of great vessels 
and the aortic arch.
While experienced US operators approach sensitivities 
close to 60-100% for diagnosing major CHDs in the second 
and third trimester, general screening specificity and sensi-
tivity differ significantly (8). Although high in tertiary care, 
such as university-associated hospitals, detection rates drop to 
≤39% when performed in community-based centers or by less 
experienced operators (9,10).
Among the various biomarkers currently available, the 
assessment of nuchal translucency prevails as one of the most 
popular screening markers for cardiac malformations (11). 
Regularly performed between gestational weeks 11-14, 
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measurement of the hypoechogenic space between skin and 
subcutaneous tissue, covering the cervical spine of the fetus, 
quantifies the risk for possible cardiac malformations. However, 
the sensitivity of this screening method depends profoundly on 
the percentile used as the cut-off point and the experience of 
the US operator conducting the examination (12,13).
A different approach utilizes maternal serum markers, 
including elevated levels of free β-hCG and lowered levels of 
PAPP-A, commonly used for screening Down's syndrome (14). 
Although highly useful in predicting chromosomal abnormali-
ties when combined, these biomarkers fall short in establishing 
stand-alone indicators for CHDs (15).
In recent years, research of the fetal products that are able 
to pass the placental barrier and enter the maternal circula-
tion has increased. Numerous studies linked specific miRNAs 
associated with cardiogenesis to placental miRNA expres-
sion (16,17). Similar to cell-free fetal DNA, these miRNAs 
enter the maternal peripheral bloodstream during pregnancy 
and allow for non-invasive prenatal testing, thus introducing 
novel biomarkers for screening and validating congenital heart 
malformations (18).
miRNAs belong to a recently discovered family of small 
endogenous non-coding RNAs and constitute an additional 
level of control in gene expression. Acting as RNA silencers 
and at the post-transcriptional level, these molecules modify 
the expression of 30-60% of human protein-encoding 
genes (19,20). Approximately 22 nucleotides long, these 
short, single-stranded RNA molecules interact with their 
target coding mRNAs to reduce translation by either reducing 
mRNA stability or inhibiting translation without target degra-
dation (21).
The various locations of the miRNA-encoding genes on 
the genome allow differentiation to be separated into 3 groups: 
Intergenic, intronic and exonic miRNAs. While intergenic 
miRNA genes reside between 2 protein-coding genes with 
their own promoters and regulatory units, intronic and exonic 
miRNA genes rely on co-transcription together with their host 
genes in intron and exon regions, respectively (22).
Deviation of an miRNA-related pathway may lead to 
serious malformations and/or early death of the affected 
mammal as shown by Bernstein et al (23) who examined 
their importance for correct development of mouse embryonic 
stem cells (ESC) through disruption of the Dicer1 gene. In 
particular, the changing miRNA expression profile during 
ESC differentiation and the inability of Dicer‑deficient ESC to 
undergo any type thereof, suggest the involvement of miRNAs 
in the regulation of transcription factors that are essential for 
cellular differentiation and survival (24).
Therefore, the present study explores hsa-miR-99a as a 
marker, examined the correlation between hsa-miR-99a and 
congenital heart malformations, and therefore, established an 
evidence-based foundation for future use in diagnostics.
Materials and methods
Patients. A total of 39 pregnant patients with an average 
age of 31.59±5.47 years and an average gestational age of 
22.22±5.20 weeks were included in the study. The participants 
were divided on grounds of fetal health and assigned to a 
control group, containing 17 women with healthy fetuses and a 
patient group, consisting of 22 women, satisfying the following 
criteria led to patient group assignment: Positive US indicating 
one or more congenital heart defects. The Ethical Scientific 
Board approved the study, patients were informed and they 
provided signed consent.
Blood sample collection and plasma preparation. Venous 
blood samples were drawn into 2x9 ml ethylenediaminetet-
raacetic acid tubes, which were centrifuged at 800 x g at first 
and subsequently the obtained supernatant was centrifuged at 
4,800 x g for an interval of 10 min at 4˚C, respectively, using 
an Eppendorf Centrifuge 5810 R (Eppendorf AG, Hamburg, 
Germany). Following the second centrifugation, the superna-
tant maternal plasma was stored in 1.5 ml Eppendorf tubes at 
‑80˚C for later miRNA extraction and analysis.
miRNA extraction. miRNA was isolated from 300 µl 
maternal plasma using the NucleoSpin® miRNA Plasma kit 
(Macherey-Nagel GmbH and Co., KG, Düren, Germany). The 
concentration of total miRNA was measured on a Nanodrop 
spectrophotometer (Thermo Fisher Scientific Inc., Waltham, 
MA, USA). The purity of each sample was determined by the 
ratio absorbance (optical density value = A260/A280).
Reverse transcription-quantitative polymerase chain reaction 
(RT-qPCR). RT of 4 µl total miRNA was performed by applying 
cDNA-miScript II RT (Qiagen GmbH, Hilden, Germany), 
according to the manufacturer's instructions, allowing further 
amplification. RT‑qPCR was performed in a LightCycler II 
(Roche Diagnostics GmbH, Mannheim, Germany), with 
the miRCURY LNA™ Universal RT microRNA PCR kit 
(Exiqon A/S, Vedbaek, Denmark) in combination with the 
Roche Master mix (Roche Diagnostics GmbH), and preceded 
the application of hsa-miR-99a-specific primers and the 
microRNA LNA™ PCR primer set, (Exiqon A/S) targeting 
the sequence: 5'-AACCCGUAGAUCCGAUCUUGUG-3'.
The results were normalized using the U6-snRNA miRNA, 
and the relative expression of hsa-miR-99a in the retrieved 
plasma samples was analyzed with the 2-∆∆Ct method. Sample 
concentrations of hsa-miR-99a and U6 were calculated in 
proportion to the globin reference gene used in 4 different 
quantities (15, 1.5, 0.15 and 0.015 ng/µl).
Statistical analysis. All the data are expressed as mean ± stan-
dard deviation non-invasive prenatal testing, and analyzed 
using Microsoft Excel 2011 version 14.4.6 (Microsoft Corp., 
Redmond, WA, USA). The statistical significance of differ-
entially expressed miRNAs was computed using Student's 
two-tailed t-test. P<0.05 was considered to indicate a statisti-
cally significant difference.
Results
Concentration of miRNA. The 39 samples had an average 
miRNA concentration of 5.92±1.89 ng/µl with a variance 
of 3.57 ng/µl, a median concentration of 5.90 ng/µl and 
P=0.15. The 22 samples collected from the patient group 
showed an average miRNA concentration of 5.54±1.99 ng/µl 
with a variance of 3.94 ng/µl and median concentration of 
5.50 ng/µl, while the control group containing 17 samples 
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exhibited an average miRNA concentration of 6.40±1.69 ng/µl 
with a variance of 2.86 ng/µl and median concentration of 
5.90 ng/µl (Table I).
hsa-miR-99a concentrations. Based upon the normalized 
U6-snRNA data, the hsa-miR-99a expression profile was 
normalized as follows: The patient group had an average 
hsa-miR-99a concentration of 1.78x10-2±3.53x10-2 ng/µl with 
a variance of 1.25x10-2 ng/µl and a median concentration of 
6.45x10-3 ng/µl, whereas the control group showed an average 
hsa-miR-99a concentration of 1.09x10-3±3.55x10-3 ng/µl with 
a variance of 1.26x10-5 ng/µl and a median concentration of 
<0.001x10-3 ng/µl. The difference between the 2 groups was 
significant with P=0.038 (Table II).
The measured and normalized data presented no signifi-
cant difference for the average concentration of miRNA, 
however the hsa-miR-99a concentration showed a statistically 
significant difference in the expression.
Discussion
In the present study, the plasma expression profile of fetal 
hsa-miR-99a was investigated in maternal peripheral blood 
of 22 pregnant patients with CHD-positive fetuses and 
17 CHD-free controls by RT-qPCR and differentially expressed 
miRNAs were identified in affected patients with significantly 
upregulated miR‑99a levels. While there was no significant 
difference between the isolated miRNA concentrations 
among the affected and control groups (P=0.15), significant 
differences were identified in normalized hsa-miR-99a 
concentrations between the 2 groups (P=0.038).
Similarly, studying the role of the miRNAs associated with 
fetal heart development, Lazar et al (25) analyzed maternal 
peripheral blood samples and reported increased hsa-let-7c 
expression levels in cases of cardiac malformations, which is 
in line with the present observations. Similarly, it is located on 
the let-7c-cluster on 21q21.1.
Thus far, numerous studies investigated the crucial role of 
miRNAs in the regulation of cell proliferation and differentia-
tion, formation of complex organ systems, such as the heart, 
and throughout pregnancy. While the majority of placental 
miRNAs expressed during the first trimester exhibit angio-
genic features, miRNAs promoting cell differentiation are 
commonly expressed during the third trimester, suggesting 
that aberrant expression of miRNAs is likely associated with 
compromised pregnancies.
Trisomy 21 (Down's syndrome) is caused by the presence of 
a third copy of the human chromosome 21 (hsa21), which leads 
to altered expression of its products, causing cardiac malforma-
tions, mental deficits and phenotypic deviation as described in 
recent literature. Located on chromosome 21, the let-7c cluster 
serves a distinguished regulatory purpose in cardiac and fetal 
development, with its products targeting mRNAs and thereby 
precisely modifying organ formation. The present results are 
in accordance with the published data of Coppola et al (26), 
in which miR-99a was also overexpressed in CHD samples. 
hsa-miR-99a is one of its products and therefore a noteworthy 
candidate for monitoring cardiomyogenesis.
The estimated average medical costs (AMCs) of 
CHD-affected children <3 years of age excess the AMC 
for non-affected children of the same age by 10-20 times, 
with the greatest cost difference observed in the care of 
infants (27). Placing a significant economic burden on the 
NHS, Connor et al (28) investigated the cost burden of CHD, 
examined the associations of the social impact on families and 
reported ‘high levels of stress in terms of finances, emotional 
drain and family member burden.’
These findings emphasize the fundamental importance of 
early screening on the identification for neonates with moderate 
or severe CHD, affected families and society in general. Early 
awareness permits further testing for associated defects in 
other organ systems, allocation of additional resources for 
proactive treatment or pregnancy termination after counseling.
Furthermore, studies of the obesity rate among pregnant 
women indicate a large-scale body mass index increase in 
the western hemisphere during the last decades, impeding 
detection further. According to Fuchs et al (29), estimates 
of maternal obesity range from 10% in France to >28% in 
the United States of America (29,30). The report concludes 
that US scans of obese women are feasible, however, they 
are accompanied by a significant decline in image quality 
and global anatomical scores, complicating identification 
of cardiac malformations further. Concisely, the success of 
fetal echocardiography depends significantly upon maternal 
obesity, equipment quality and operator proficiency.
Thus, it is reasonable to assume that identification of supple-
mental methods prior and in addition to second trimester US 
examination benefit early, accurate and operator‑independent 
assessment of cardiac anomalies significantly. The early 
awareness and accurate diagnosis of CHDs allow for informed 
decisions on treatment options, including termination, while 
appropriate follow-up and delivery in tertiary care centers 
should improve overall perinatal survival in those pregnancies 
that continued.
In early embryonic development, following gastrulation 
and subsequent formation of the 3 germ layers, organ develop-
ment begins with the formation of the human heart (31). As 
Table I. Concentration of miRNA.
 Patient group Control group
Total miRNA concentration (n=22), ng/µl (n=17), ng/µl
Average ± SD 5.54±1.99  6.40±1.69
Median 5.50 5.90
SD, standard deviation.
Table II. Concentration of miR-99a.
miR-99a Patient group Control group
concentration (n=22), ng/µl (n=17), ng/µl
Average ± SD 1.78x10-2±3.53x10-2 1.09x10-3±3.55x10-3
Median 6.45x10-3 <0.001x10-3
SD, standard deviation.
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morphogenesis, growth and integrated function are essential 
for survival and require precise cardiac gene expression, 
deviations in heart development may result in congenital 
heart disease, the most frequent form of major birth defects 
in humans (32).
These pathological alterations present at birth, classified 
as CHDs, affect the structure and function of the heart. Based 
on size, location and other associated defects, these malforma-
tions differ in severity and determine survival (33).
The crucial role of miRNAs in animal development is best 
explained by the results of their absence, such as due to the 
prior mentioned disruption of the Dicer1 gene, significantly 
altering the miRNA formation. Dicer1‑deficient mice suffer 
depletion of functional mature miRNAs and exhibit develop-
mental arrest during gastrulation, causing lethality early in 
development (23). In particular, cardiac‑specific knockout of 
Dicer later in development results in severe dilated cardiomy-
opathy, heart failure and postnatal lethality (32).
Organisms contain a large set of different miRNA families 
within their tissues, with ≥1 miRNA specifically expressed per 
tissue, such as in muscle or brain (33). While the miRNA-133 
family embodies the most abundant miRNA group expressed 
in muscle tissue, other families, such as the miRNA-1 family, 
were also positively identified as muscle‑specific miRNAs. 
However, miRNA-208 is the only known miRNA exclusively 
expressed in cardiac tissue thus far (34,35).
Cardiac and muscle-specific expression of the highly 
conserved miRNA-1 (miRNA-1-1, miRNA-1-2 and 
miRNA-206) and miRNA-133 (miRNA-133a, -133a-2 and 
miRNA-133b) families follow a strict spatiotemporal pattern in 
vertebrates (35). In a gain-of-function study by Chen et al (35), 
overexpression of miRNA-1 in transgenic Xenopus laevis 
led to thin-walled ventricles due to premature myocyte 
differentiation and lethality in early embryonic development. 
Concordantly, overexpression of miRNA-1 in developing 
Xenopus laevis resulted in accelerated myogenic differentia-
tion and decreased cardiac tissue proliferation, and while the 
exact target structures differ, misexpression of miRNA-133 
also led to pathological tissue formation, frequently including 
disorganized looping and chamber formation (36).
The cardiac‑specific miRNA‑208 family (miRNA‑208a, 
miRNA-208b and miRNA-499) induces similar patho-
logical conditions in hosts following overexpression, such 
as gain-of-function studies in mice with miRNA-208a 
misexpression induced cardiac hypertrophy and conduction 
deficits (36).
While current research on miR-99a is rare or generally 
focuses on the oncological role, there are only a few studies 
regarding the role of miR-99a in heart development and func-
tion. Of those, the majority focus on its role in recovering 
from myocardial infarction when miR-99a is overexpressed. 
The present study shows the overexpression of miR-99a in the 
maternal plasma of CHD fetuses. More extensive investigations 
are required to identify reliable miRNA-based biomarkers for 
the prenatal detection of CHDs.
In conclusion, in order to evaluate the role of miRNAs in 
the development of CHDs, the present study found differen-
tially expressed levels of hsa-miR-99a from pregnant patients 
positively screened for fetal CHD and pregnant women without 
any signs of fetal malformation. miR-99a is a prospective 
novel biomarker that provides valuable information for further 
research of predictive markers and possible therapeutic target 
structures of cardiac malformation at a molecular level.
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